Venture capital pours more money into RNA medicines with the launch of Replicate

Following the success of Moderna, BioNTech and their coronavirus vaccines, money is now pouring into RNA-focused companies, with the latest batch announced Wednesday. Backed by $40 million from the venture firm Apple Tree Partners, Replicate Biosciences has officially launched, attempting to treat diseases with the help of RNA that reproduces itself.